Search research articles
Contact Us
Filters
Showing results (111-120 of 143) with videos related to
Page
of 15
Sort By:
In Vivo (Athens, Greece)
|
April 30, 2024
Targeting Methionine Addiction Combined With Low-dose Irinotecan Arrested Colon Cancer in Contrast to High-dose Irinotecan Alone, Which Was Ineffective, in a Nude-mouse Model
Motokazu Sato, Kohei Mizuta, Qinghong Han, et al.
Anticancer Research
|
July 26, 2024
Recombinant Methioninase Is Selectively Synergistic With Doxorubicin Against Wild-type Fibrosarcoma Cells Compared to Normal Cells and Overcomes Highly-Doxorubicin-resistant Fibrosarcoma
Sei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research
|
February 29, 2024
Extensive Synergy Between Recombinant Methioninase and Eribulin Against Fibrosarcoma Cells But Not Normal Fibroblasts
Sei Morinaga, Qinghong Han, Yutaro Kubota, et al.
Anticancer Research
|
August 28, 2024
Recombinant Methioninase Increases Eribulin Efficacy 16-fold in Highly Eribulin-resistant HT1080 Fibrosarcoma Cells, Demonstrating Potential to Overcome the Clinical Challenge of Drug-resistant Soft-tissue Sarcoma
Sei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research
|
April 28, 2025
Recombinant Methioninase and Cisplatinum Act Synergistically to Inhibit Lewis Lung Carcinoma Cells But Not Normal Fibroblasts
Yohei Asano, Qinghong Han, Kohei Mizuta, et al.
Cancer Chemotherapy and Pharmacology
|
November 10, 2019
The combination of oral-recombinant methioninase and azacitidine arrests a chemotherapy-resistant osteosarcoma patient-derived orthotopic xenograft mouse model
Takashi Higuchi, Norihiko Sugisawa, Jun Yamamoto, et al.
Anticancer Research
|
May 31, 2024
DNA-Binding Agent Trabectedin Combined With Recombinant Methioninase Is Synergistic to Decrease Fibrosarcoma Cell Viability and Induce Nuclear Fragmentation But Not Synergistic on Normal Fibroblasts
Sei Morinaga, Qinghong Han, Yutaro Kubota, et al.
Cancer Letters
|
August 3, 2020
Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model
Jun Yamamoto, Kentaro Miyake, Qinghong Han, et al.
Cancer Letters
|
June 22, 2018
Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer
Kei Kawaguchi, Kentaro Miyake, Qinghong Han, et al.
Oncotarget
|
November 22, 2017
Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model
Kei Kawaguchi, Kentaro Igarashi, Shukuan Li, et al.
Page
of 15
Search research articles
Search
Showing results (111-120 of 143) with videos related to
Sort By:
Page
of 15
In Vivo (Athens, Greece)
|
April 30, 2024
Targeting Methionine Addiction Combined With Low-dose Irinotecan Arrested Colon Cancer in Contrast to High-dose Irinotecan Alone, Which Was Ineffective, in a Nude-mouse Model
Motokazu Sato, Kohei Mizuta, Qinghong Han, et al.
Anticancer Research
|
July 26, 2024
Recombinant Methioninase Is Selectively Synergistic With Doxorubicin Against Wild-type Fibrosarcoma Cells Compared to Normal Cells and Overcomes Highly-Doxorubicin-resistant Fibrosarcoma
Sei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research
|
February 29, 2024
Extensive Synergy Between Recombinant Methioninase and Eribulin Against Fibrosarcoma Cells But Not Normal Fibroblasts
Sei Morinaga, Qinghong Han, Yutaro Kubota, et al.
Anticancer Research
|
August 28, 2024
Recombinant Methioninase Increases Eribulin Efficacy 16-fold in Highly Eribulin-resistant HT1080 Fibrosarcoma Cells, Demonstrating Potential to Overcome the Clinical Challenge of Drug-resistant Soft-tissue Sarcoma
Sei Morinaga, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research
|
April 28, 2025
Recombinant Methioninase and Cisplatinum Act Synergistically to Inhibit Lewis Lung Carcinoma Cells But Not Normal Fibroblasts
Yohei Asano, Qinghong Han, Kohei Mizuta, et al.
Cancer Chemotherapy and Pharmacology
|
November 10, 2019
The combination of oral-recombinant methioninase and azacitidine arrests a chemotherapy-resistant osteosarcoma patient-derived orthotopic xenograft mouse model
Takashi Higuchi, Norihiko Sugisawa, Jun Yamamoto, et al.
Anticancer Research
|
May 31, 2024
DNA-Binding Agent Trabectedin Combined With Recombinant Methioninase Is Synergistic to Decrease Fibrosarcoma Cell Viability and Induce Nuclear Fragmentation But Not Synergistic on Normal Fibroblasts
Sei Morinaga, Qinghong Han, Yutaro Kubota, et al.
Cancer Letters
|
August 3, 2020
Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model
Jun Yamamoto, Kentaro Miyake, Qinghong Han, et al.
Cancer Letters
|
June 22, 2018
Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer
Kei Kawaguchi, Kentaro Miyake, Qinghong Han, et al.
Oncotarget
|
November 22, 2017
Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model
Kei Kawaguchi, Kentaro Igarashi, Shukuan Li, et al.
Page
of 15